Cancer

Health Union Releases 2024 Findings of “In America” and “Patient Experience” Syndicated Healthcare Research, Offering Unmatched Patient Insights

With data from over 37,000 individuals across 50+ conditions, Health Union's 2024 syndicated healthcare research findings provide fresh perspectives on…

1 year ago

Harbinger Health Announces New Partnership with Leading Cancer Center to Accelerate Clinical Evidence Generation

Collaboration to include future projects developing novel tools for cancer screening and detection that leverage premier academic institution's large set…

1 year ago

Function Health Expands Nationwide with Roll Out into New York and New Jersey

Amidst the growing prevalence of chronic diseases, Function Health's rollout provides millions more Americans access to full-body preventative lab testing…

1 year ago

GenomOncology and Genomenon Partner to Enhance Germline Variant Classification and Genomic Reporting

CLEVELAND, Nov. 7, 2024 /PRNewswire/ -- GenomOncology, a precision medicine software company, and Genomenon, a leading genomic intelligence company, today…

1 year ago

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is…

1 year ago

Ludwig Enterprises Begins PCR Validation Test Process

Final step before the full launch of breast cancer screening program, Revealia™SPARKS, NV / ACCESSWIRE / November 7, 2024 /…

1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by…

1 year ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…

1 year ago

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product…

1 year ago